- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00220480
A Naturalistic Study of the Efficacy and Safety of Escitalopram in Treatment Resistant Depression
Studieöversikt
Studietyp
Inskrivning (Förväntat)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
-
Haifa, Israel
- Rekrytering
- Rambam Medical Center
-
Kontakt:
- Leah Fostick, MA
- Telefonnummer: +972-3-5357805
- E-post: Leah.Fostick@sheba.health.gov.il
-
Ness Ziona, Israel
- Rekrytering
- Ness Ziona Mental Health Center
-
Kontakt:
- Leah Fostick, MA
- Telefonnummer: +972-3-5357805
- E-post: Leah.Fostick@sheba.health.gov.il
-
Petach Tikva, Israel
- Rekrytering
- Gehah Mental Health Center
-
Kontakt:
- Leah Fostick, MA
- Telefonnummer: +972-3-5357805
- E-post: Leah.Fostick@health.gov.il
-
Ramat-Gan, Israel, 52621
- Rekrytering
- Chaim Sheba Medical Center
-
Kontakt:
- Leah Fostick, MA
- Telefonnummer: +972-3-5357805
- E-post: Leah.Fostick@sheba.health.gov.il
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
Any patient who meets all of the following criteria is eligible for inclusion in the Prospective phase I of the study:
- The patient is able to read and understand the patient information sheet.
- Prior to any screening procedures, the patient must have signed the informed consent form. No study-related procedures may be performed before the patient has signed the form.
- The patient is an in- or outpatient, male or female.
- The patient is between 18 and 65 years of age.
- The patient suffers from a diagnosis of recurrent Major Depressive Disorder (current episode assessed with the MINI), moderate or severe, according to DSM-IV-TR criteria (classification code = 296.3x).
- The patient has a total score of 22 or higher on the MADRS.
- The patient has been treated for the current episode with an antidepressant (other than escitalopram or venlafaxine) prescribed continuously at the optimal dose (see table Appendix 1) for at least the 4 weeks preceding selection (AD1).
- The investigator considers switching treatment to venlafaxine (AD2), prescribing it at its optimal dose, defined by the study protocol.
Exclusion Criteria:
Any patient who meets one or more of the following criteria cannot be included in the screening phase of the study:
- The patient has previously participated in this study.
- Results from blood sampling at selection show for the antidepressant prescribed (AD1), that plasma concentration is below the expected threshold according to time of last intake.
- The patient has taken another antidepressant in combination to the antidepressant to which he/she is considered as non-responder (AD1).
The patient has one or more of the following conditions:
- Any current psychiatric disorder established as the principal diagnosis other than Major depressive episode as defined in the DSM-IV-TR (assessed with the MINI).
- Any Substance disorder (except nicotine and caffeine) within the previous 6 months as defined in the DSM-IV-TR.
- Any severe personality disorder according to investigator clinical judgement, that might compromise the study.
The patient uses disallowed recent or concomitant medication within the specified time periods:
- oral antipsychotic drugs within 2 months and depot antipsychotic preparations within the past 6 months.
- ECT within the past 6 months.
- lithium, carbamazepine, valproate or valpromide within the past month.
- any benzodiazepines at a dose higher than 10 mg diazepam or equivalent, within the last week.
- any non-benzodiazepine anxiolytics within the last week.
- serotonin agonists within the last week.
- any other drug with potential psychotropic effects within the last week.
- any drug known to lower blood pressure in the last week.
- The patient has been treated with any investigational product within 3 months prior to screening.
- The patient has been treated during the current episode with escitalopram or venlafaxine.
- The patient has a history of severe drug allergy or hypersensitivity, or known hypersensitivity to escitalopram or venlafaxine.
- The patient started (or will start) formal psychotherapy in the month preceding inclusion.
- The patient has a previous history of convulsive disorder other than a single childhood febrile seizure.
- The patient presents evidence of urinary retention or glaucoma.
- The patient has a serious illness and/or serious sequelae thereof, including liver or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, infectious, neoplastic, or metabolic disturbance.
- The patient has, in the opinion of the investigator, on the basis of a physical examination, medical history and vital signs, a comorbid conditions(s) that would render inclusion in the study unsafe.
- The patient takes medication that, in the opinion of the investigator, could interfere with the assessments of safety, tolerability, or efficacy.
- The patient, in the opinion of the investigator, is unlikely to comply with the clinical study protocol or is unsuitable for any reason
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
MADRS
Tidsram: 8 to 10 weeks
|
8 to 10 weeks
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Mentala störningar
- Humörstörningar
- Depressiv sjukdom
- Depressiv sjukdom, major
- Läkemedels fysiologiska effekter
- Neurotransmittormedel
- Molekylära mekanismer för farmakologisk verkan
- Psykotropa droger
- Serotoninupptagshämmare
- Neurotransmittorupptagshämmare
- Membrantransportmodulatorer
- Serotoninmedel
- Antidepressiva medel
- Antidepressiva medel, andra generationen
- Citalopram
Andra studie-ID-nummer
- SHEBA-04-3434-JZ-CTIL
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Depressiv sjukdom, major
-
Assistance Publique - Hôpitaux de ParisAvslutadMaj-Hemalin | Fechtners syndrom (störning) | Epsteins syndrom (störning) | MYH9-relaterade sjukdomarFrankrike
-
University Medical Center GoettingenAvslutadMajor depressiv sjukdom | Depressiv episodTyskland
-
Wyeth is now a wholly owned subsidiary of PfizerAvslutadDepressiv sjukdom, allvarlig depressiv sjukdomFörenta staterna
-
Shalvata Mental Health CenterOkändSTOR depressiv sjukdomIsrael
-
York UniversityCentre for Addiction and Mental HealthUpphängdStörning, major depressivKanada
-
University of WarsawHar inte rekryterat ännuMåttlig depressiv episod | Mild depressiv episod
-
Seasons Biotechnology (Taizhou) Co., Ltd.AvslutadMajor depressiv sjukdom (MDDIndien
-
Gangnam Severance HospitalAvslutadMajor depressiv sjukdom (MDD)Korea, Republiken av
-
Omni C&SAnmälan via inbjudanDepressiv sjukdom | Major depressiv sjukdom | Depressiv episodKorea, Republiken av
-
Seasons Biotechnology (Taizhou) Co., Ltd.AvslutadMajor depressiv sjukdom (MDD)Indien
Kliniska prövningar på escitalopram
-
Perry RenshawAvslutadDepression | Substansanvändning | Dubbel diagnosFörenta staterna
-
First Affiliated Hospital of Zhejiang UniversityRekryteringTonåring | Depressiv sjukdomKina
-
Rigshospitalet, DenmarkUniversity of Cambridge; Lundbeck FoundationAvslutad
-
Taipei Veterans General Hospital, TaiwanNational Tsing Hua University,TaiwanAvslutadHuvud- och halscancerTaiwan
-
University of NebraskaRekrytering
-
Centre Hospitalier Universitaire VaudoisHar inte rekryterat ännuFarmakogenetisk testning
-
Shanghai 7th People's HospitalHar inte rekryterat ännuDepressiv sjukdom, majorKina
-
Shanghai Mental Health CenterJiangsu Nhwa Pharmaceutical Co., Ltd.Avslutad
-
Chonnam National University HospitalRekryteringMajor depressiv sjukdomKorea, Republiken av
-
Johns Hopkins UniversityMedical University of South Carolina; University of South Carolina; University... och andra samarbetspartnersRekrytering